Sanara MedTech Croissance future
Future contrôle des critères 1/6
Sanara MedTech devrait augmenter ses bénéfices et ses revenus de 10% et de 16.1% par an respectivement, tandis que le BPA devrait croître de croître de 15.6% par an.
Informations clés
10.0%
Taux de croissance des bénéfices
15.6%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.1% |
| Taux de croissance des recettes | 16.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 13 Nov 2024 |
Mises à jour récentes de la croissance future
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Nov 15
Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Mar 22Recent updates
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Nov 15Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump
Sep 05Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt
Aug 14Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story
May 23Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?
Nov 15Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)
May 22Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Mar 22Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure
Sep 06Sanara MedTech reports Q2 results
Aug 15Here's Why We're Not At All Concerned With Sanara MedTech's (NASDAQ:SMTI) Cash Burn Situation
Dec 31Sanara MedTech: Technology For Faster Healing Wounds
Dec 08Sanara Medtech inks exclusive partnership with Pixalere Healthcare
Jun 04Companies Like Sanara MedTech (NASDAQ:SMTI) Can Afford To Invest In Growth
May 18Neil Cataldi From Blueprint Discusses Sanara MedTech
May 03The Sanara MedTech (NASDAQ:SMTI) Share Price Has Soared 510%, Delighting Many Shareholders
Feb 19
Is Sanara MedTech Inc. (NASDAQ:SMTI) Popular Amongst Insiders?
Dec 28Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 112 | -7 | N/A | N/A | 1 |
| 12/31/2025 | 99 | -10 | N/A | N/A | 1 |
| 12/31/2024 | 83 | -11 | N/A | N/A | 1 |
| 9/30/2024 | 78 | -8 | -2 | -2 | N/A |
| 6/30/2024 | 72 | -7 | -3 | -3 | N/A |
| 3/31/2024 | 68 | -5 | -3 | -3 | N/A |
| 12/31/2023 | 65 | -4 | -4 | -3 | N/A |
| 9/30/2023 | 63 | -8 | -3 | -3 | N/A |
| 6/30/2023 | 60 | -9 | -4 | -6 | N/A |
| 3/31/2023 | 54 | -6 | -6 | -5 | N/A |
| 12/31/2022 | 46 | -8 | -6 | -6 | N/A |
| 9/30/2022 | 38 | -7 | -8 | -7 | N/A |
| 6/30/2022 | 30 | -8 | -9 | -6 | N/A |
| 3/31/2022 | 27 | -10 | -6 | -6 | N/A |
| 12/31/2021 | 24 | -8 | -6 | -5 | N/A |
| 9/30/2021 | 22 | -5 | -5 | -4 | N/A |
| 6/30/2021 | 20 | -4 | -3 | -3 | N/A |
| 3/31/2021 | 17 | -4 | -4 | -3 | N/A |
| 12/31/2020 | 16 | -4 | -6 | -4 | N/A |
| 9/30/2020 | 14 | -6 | -6 | -4 | N/A |
| 6/30/2020 | 13 | -5 | -6 | -4 | N/A |
| 3/31/2020 | 13 | -4 | -6 | -4 | N/A |
| 12/31/2019 | 12 | -3 | -4 | -2 | N/A |
| 9/30/2019 | 11 | -1 | -2 | -1 | N/A |
| 6/30/2019 | 10 | 0 | -1 | -1 | N/A |
| 3/31/2019 | 9 | 0 | 0 | 0 | N/A |
| 12/31/2018 | 9 | 0 | 0 | 1 | N/A |
| 9/30/2018 | 8 | 0 | 1 | 1 | N/A |
| 6/30/2018 | 7 | 0 | N/A | 0 | N/A |
| 3/31/2018 | 7 | 0 | N/A | 0 | N/A |
| 12/31/2017 | 6 | 0 | N/A | 0 | N/A |
| 9/30/2017 | 6 | 0 | N/A | 0 | N/A |
| 6/30/2017 | 6 | 0 | N/A | 1 | N/A |
| 3/31/2017 | 6 | -1 | N/A | 0 | N/A |
| 12/31/2016 | 6 | -1 | N/A | 0 | N/A |
| 9/30/2016 | 4 | -1 | N/A | 0 | N/A |
| 6/30/2016 | 4 | -2 | N/A | -1 | N/A |
| 3/31/2016 | 3 | -1 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -2 | N/A | -1 | N/A |
| 9/30/2015 | 3 | -1 | N/A | -1 | N/A |
| 6/30/2015 | 3 | -2 | N/A | -1 | N/A |
| 3/31/2015 | 3 | -2 | N/A | -1 | N/A |
| 12/31/2014 | 3 | -3 | N/A | -2 | N/A |
| 9/30/2014 | 2 | -4 | N/A | -2 | N/A |
| 6/30/2014 | 2 | -5 | N/A | -2 | N/A |
| 3/31/2014 | 2 | -4 | N/A | -2 | N/A |
| 12/31/2013 | 2 | -4 | N/A | -2 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: SMTI devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: SMTI devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: SMTI devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de SMTI ( 16.1% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de SMTI ( 16.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de SMTI devrait être élevé dans 3 ans